Viking Therapeutics Reports Positive 52|Week Data from Phase 2b ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

News & Events. Investors. << Back. Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non- ...

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study ...

PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of ...

Viking Therapeutics Reports Positive 52-week Histologic Data From ...

(RTTNews) - Viking Therapeutics, Inc. (VKTX) Tuesday reported positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in ...

Viking Therapeutics Reports Positive 52-Week Data from Phase 2b ...

The response rate, defined by a reduction in liver fat ≥30%, ranged from 64% to 88%, with all VK2809 groups showing considerable improvements ...

Viking Therapeutics (VKTX) Reports Positive 52-Week Histologic ...

(NASDAQ: VKTX) today announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel liver-selective ...

Viking Therapeutics Reports New Data from VK2735 Obesity ...

... reported 13-week Phase 2 VENTURE study of VK2735 dosed as a subcutaneous injection. As previously reported, patients receiving weekly doses ...

EX-99.1 - SEC.gov

During the first quarter of 2024, Viking announced positive top-line results from a Phase 2 study called VENTURE. ... Reported Positive 52-Week Histologic Data ...

Viking Therapeutics Reports Positive 52-week Histologic Data From ...

Viking Therapeutics, Inc. (VKTX) Tuesday reported positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with ...

Viking Therapeutics Reports Third Quarter 2024 Financial Results ...

During the second quarter, the company announced positive 52-week histology results from the Phase 2b VOYAGE trial evaluating VK2809 in ...

Viking Therapeutics Reports Third Quarter 2024 Financial Results ...

During the second quarter, the company announced positive 52-week histology results from the Phase 2b VOYAGE trial evaluating VK2809 in patients ...

VKTX | Viking Therapeutics Announces Positive 52-Week Histologic ...

Report. VKTX | Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy ...

Viking Therapeutics Presents Positive Data from VK2735 for ...

Results from the VENTURE Phase II trial and a Phase I oral formulation study found that VK2735, a novel a dual GLP-1 and GIP receptor ...

Viking Therapeutics, Inc. (1VT.F) - Yahoo Finance

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic ...

News & Events - Viking Therapeutics

We expect to report topline results from both the VENTURE Phase 2 ... We look forward to reporting the 52-week biopsy data from this study in the ...

Viking Therapeutics - BioSpace

Viking Therapeutics · Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non- ...

Viking stock fluctuates amid manufacturing concerns with obesity pill

Shares in Viking Therapeutics jumped after the company shared positive data ... Viking Therapeutics said it will begin a 13-week Phase II study of ...

News & Events - Viking Therapeutics

News & Events. Investors. << Back. Viking Therapeutics Announces Positive Top-Line Results from Phase 2b ... week biopsy data from this study in ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

Viking Therapeutics, Inc. announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel ...

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity ...

The presentations will showcase results from: 1) The Phase 2 VENTURE trial evaluating a 13-week subcutaneous treatment of VK2735 in obese ...